CLINICAL TRIALS PROFILE FOR ENFLURANE

All Clinical Trials for ENFLURANE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01452256 ↗	Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery	Completed	Cantonal Hospital of St. Gallen	Phase 4	2011-12-01	Desflurane and its effect on postoperative morbidity and mortality in patients undergoing thoracic surgery. Halothane, enflurane, isoflurane, sevoflurane, and desflurane are volatile anesthetics, a group of general anesthetics. Because of the hypnotic effects of these agents, attention has mainly focused on the central nervous system. In the last 10 years, however, numerous studies have reported that volatile anesthetic agents interact with membrane structures of the myocardium and thereby attenuate cardiac mechanical dysfunction and limit ultrastructural abnormality on reperfusion after prolonged ischemia in the myocyte. Anesthetic-induced preconditioning has become a main topic in cardiac research worldwide - Trial with medicinal product
NCT01452256 ↗	Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery	Completed	Kantonsspital Münsterlingen	Phase 4	2011-12-01	Desflurane and its effect on postoperative morbidity and mortality in patients undergoing thoracic surgery. Halothane, enflurane, isoflurane, sevoflurane, and desflurane are volatile anesthetics, a group of general anesthetics. Because of the hypnotic effects of these agents, attention has mainly focused on the central nervous system. In the last 10 years, however, numerous studies have reported that volatile anesthetic agents interact with membrane structures of the myocardium and thereby attenuate cardiac mechanical dysfunction and limit ultrastructural abnormality on reperfusion after prolonged ischemia in the myocyte. Anesthetic-induced preconditioning has become a main topic in cardiac research worldwide - Trial with medicinal product
NCT01452256 ↗	Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery	Completed	University Hospital Inselspital, Berne	Phase 4	2011-12-01	Desflurane and its effect on postoperative morbidity and mortality in patients undergoing thoracic surgery. Halothane, enflurane, isoflurane, sevoflurane, and desflurane are volatile anesthetics, a group of general anesthetics. Because of the hypnotic effects of these agents, attention has mainly focused on the central nervous system. In the last 10 years, however, numerous studies have reported that volatile anesthetic agents interact with membrane structures of the myocardium and thereby attenuate cardiac mechanical dysfunction and limit ultrastructural abnormality on reperfusion after prolonged ischemia in the myocyte. Anesthetic-induced preconditioning has become a main topic in cardiac research worldwide - Trial with medicinal product
NCT01452256 ↗	Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery	Completed	University Hospital, Basel, Switzerland	Phase 4	2011-12-01	Desflurane and its effect on postoperative morbidity and mortality in patients undergoing thoracic surgery. Halothane, enflurane, isoflurane, sevoflurane, and desflurane are volatile anesthetics, a group of general anesthetics. Because of the hypnotic effects of these agents, attention has mainly focused on the central nervous system. In the last 10 years, however, numerous studies have reported that volatile anesthetic agents interact with membrane structures of the myocardium and thereby attenuate cardiac mechanical dysfunction and limit ultrastructural abnormality on reperfusion after prolonged ischemia in the myocyte. Anesthetic-induced preconditioning has become a main topic in cardiac research worldwide - Trial with medicinal product
NCT00815269 ↗	Vasodilation Effect of Inhalational Anesthetics	Completed	Nanjing Medical University	N/A	2008-12-01	Previous studies on animals suggest that inhalational anesthetics can reduce vascular tension in vitro resulting in vasodilation and decrease in blood pressure. This role for inhalational anesthetics has essential clinical implications such as the condition of sepsis or septic shock or other shock-associated states during which the blood vessel constricts strongly and leads to circulation dysfunction. The vasodilation property of these anesthetics including halothane, isoflurane, sevoflurane, desflurane and enflurane enables them to be better options than other general anesthetics in many clinical conditions needing the vasculature to be dilated. The investigators hypothesized that these inhalational anesthetics can evoke vasodilation measured with ultrasonography during general anesthesia in vivo as the in vitro studies displayed.

Clinical Trial Conditions for ENFLURANE

Condition Name

Condition Name for ENFLURANE
Intervention	Trials
General Anesthesia	1
Myocardial Reperfusion Injury	1
Thoracic Surgery	1

Condition MeSH

Condition MeSH for ENFLURANE
Intervention	Trials
Reperfusion Injury	1
Myocardial Reperfusion Injury	1
Aneurysm, Dissecting	1

Clinical Trial Locations for ENFLURANE

Trials by Country

+

−

Trials by Country for ENFLURANE
Location	Trials
Switzerland	2
China	1

Clinical Trial Progress for ENFLURANE

Clinical Trial Phase

Clinical Trial Phase for ENFLURANE
Clinical Trial Phase	Trials
Phase 4	2
N/A	1

Clinical Trial Status

Clinical Trial Status for ENFLURANE
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for ENFLURANE

Sponsor Name

Sponsor Name for ENFLURANE
Sponsor	Trials
University Hospital, Basel, Switzerland	2
University Hospital Inselspital, Berne	1
University of Zurich	1

Sponsor Type

Sponsor Type for ENFLURANE
Sponsor	Trials
Other	10

Enflurane: Clinical Trials, Market Analysis, and Projections

Introduction

Enflurane, a volatile anesthetic introduced in the late 1960s, plays a crucial role in inducing and maintaining general anesthesia. Here, we will delve into the current state of clinical trials, market analysis, and future projections for enflurane.

Clinical Trials and Safety Profile

Ongoing Studies

While there are no recent, highly publicized clinical trials specifically focused on enflurane alone, studies comparing different anesthetic agents often include enflurane. For instance, a study comparing the safety and efficacy of inhaled isoflurane versus intravenous propofol for sedation in ICU patients highlights the broader context of inhalation anesthesia research, which can indirectly inform about enflurane's safety and efficacy[4].

Safety and Efficacy

A large-scale study involving 17,201 patients compared the safety and efficacy of four general anesthetic agents, including enflurane. The study found that while the rates of serious adverse outcomes were low, enflurane did have some contributing factors in a small number of deaths and other adverse outcomes. However, most of these outcomes were minor[1].

Market Analysis

Current Market Size and Growth

The global market for enflurane is part of the larger inhalation anesthesia market. As of the latest reports, the enflurane market is expected to grow, albeit at a slower pace compared to newer anesthetics. The global enflurane market is projected to reach $282.70 million by 2030, growing at a CAGR of roughly 5% over the next five years[3].

Key Drivers and Challenges

The growth of the enflurane market is driven by several factors:

• Increasing Surgical Procedures: The rise in the number of surgical procedures, particularly minimally invasive surgeries, increases the demand for effective anesthetic agents.
• Technological Advancements: Improvements in anesthesia delivery systems enhance the safety and efficacy of enflurane.
• Expanding Healthcare Infrastructure: Economic improvements in emerging markets and investments in healthcare infrastructure boost the availability of surgical services[3].

However, enflurane faces challenges such as:

• Side Effects: Enflurane is associated with side effects like hypotension and respiratory depression.
• Competition from Newer Anesthetics: Newer anesthetics with fewer side effects and faster recovery times, such as sevoflurane and desflurane, pose significant competition.
• Regulatory Hurdles: Stringent regulatory approval processes and market resistance from practitioners accustomed to established anesthetics complicate market penetration[3].

Market Segmentation and Regional Outlook

End-Use Segmentation

The enflurane market is segmented based on end-use, with key segments including:

• Hospitals: The primary users of enflurane due to the high volume of surgical procedures.
• Ambulatory Surgical Centers: These centers are increasingly adopting enflurane for outpatient surgeries[3].

Regional Outlook

The market is studied across various regions:

• Americas: This includes the United States, Canada, Mexico, and countries in Latin America.
• Asia-Pacific: Countries such as China, India, Japan, and Australia are significant markets.
• Europe, Middle East & Africa: This region includes countries like Germany, France, Italy, and those in the Middle East and Africa[3].

Competitive Landscape

Key Players

The enflurane market is dominated by large pharmaceutical companies, including:

• AbbVie Inc.
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• Drägerwerk AG & Co. KGaA
• Hikma Pharmaceuticals PLC
• Sanofi S.A.[3].

Future Projections

Market Growth

Despite the challenges, the enflurane market is expected to grow, driven by the increasing adoption of minimally invasive surgeries and the expansion of healthcare infrastructure in emerging markets. Innovations in precise dosage control mechanisms, effective drug combinations, and biochemical modifications to minimize side effects are expected to sustain growth[3].

Emerging Markets

Emerging markets, particularly in Latin America and the Middle East & Africa, offer significant growth opportunities due to increasing healthcare spending and the adoption of advanced anesthetic technologies[2].

Key Takeaways

• Clinical Trials: While specific trials on enflurane are limited, broader studies on inhalation anesthesia inform its safety and efficacy.
• Market Growth: The enflurane market is projected to grow at a CAGR of roughly 5% until 2030.
• Key Drivers: Increasing surgical procedures, technological advancements, and expanding healthcare infrastructure drive market growth.
• Challenges: Side effects, competition from newer anesthetics, and regulatory hurdles are significant challenges.
• Regional Outlook: The Americas, Asia-Pacific, and Europe, Middle East & Africa are key regions for the enflurane market.

FAQs

What are the primary uses of enflurane?

Enflurane is primarily used for inducing and maintaining general anesthesia in surgical settings, including both induction and maintenance phases.

What are the key side effects associated with enflurane?

Enflurane is associated with side effects such as hypotension and respiratory depression.

Which regions offer the most growth potential for the enflurane market?

Emerging markets in Latin America and the Middle East & Africa offer significant growth potential due to increasing healthcare spending and the adoption of advanced anesthetic technologies.

How does enflurane compare to other inhalation anesthetics like sevoflurane?

Enflurane faces competition from newer anesthetics like sevoflurane, which have faster recovery times and fewer side effects, making them preferred choices in many clinical environments.

What are the main drivers of the enflurane market growth?

The main drivers include the increasing number of surgical procedures, technological advancements in anesthesia delivery, and the expansion of healthcare infrastructure in emerging markets.

Sources

1. Multicenter study of general anesthesia. II. Results - PubMed
2. Inhalation Anesthesia Market Size And Share Report, 2030 - Grand View Research
3. Enflurane Market worth $282.70 million by 2030, growing at a CAGR - OpenPR
4. Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S - UCLA Health
5. North America Inhalation Anesthesia Market Size & Outlook, 2030 - Grand View Research